Project Firefly
Confidential summary for informational purposes only — not an offer or solicitation. Details provided to qualified parties upon request/NDA.
Company Overview
Project Firefly is a US-established pharmaceutical company focused on high-value branded respiratory products.
The company maintains a truly global footprint with:
Manufacturing, R&D, and marketing operations in over 25 countries
Registered entities in the United States, United Kingdom, Ireland, India, and Australia
This investment opportunity is specifically for equity in the US company, enabling investors to participate directly in the fast-growing US respiratory market while leveraging the group’s established global infrastructure and supply chain.
The US Respiratory Market Opportunity
The US respiratory drugs market is experiencing strong structural growth, driven by:
Rising prevalence of chronic respiratory diseases (COPD, asthma, cystic fibrosis, etc.)
Increased disease awareness and diagnosis rates
Growing demand for innovative and effective therapies
Current market size exceeds $30 billion and continues to expand, creating substantial opportunity for specialized, high-value branded products with strong clinical positioning and limited generic threat.
Product Portfolio & Regulatory Strength
Four differentiated NDA-approved branded respiratory products:
Product A – Dry Powder Inhalation – Approved Dec 1996
Product B – Approved Oct 2010
Product C – Approved Mar 2016
Product D – IV Injectable – Approved Oct 2023
Key advantages:
One product protected by patent until 2032
Remaining three products face very minimal generic risk in the near-to-medium term
Highly specialized, safe products with no major side effects reported
Already marketed successfully in 28+ countries globally
Established US market presence with existing relationships across respiratory hospitals, clinics, and specialists
Financial Profile & Growth Potential
Current topline revenue: ≈ $40 million
Forecasted high gross margins: >82% over the next 4 years
Expected strong and lucrative EBITDA generation
Robust, ready-to-execute marketing & sales expansion plan targeting accelerated US penetration
Significant headroom to grow market share in both existing and new indications
Projected Return on Investment (ROI) in less than 30 months for participating investors
Investment Opportunity
Project Firefly is inviting long-term equity partners to accelerate US growth and maximize the value of this rare, high-margin respiratory portfolio.
Minimum investment: US$4 million and upwards
Direct equity participation in the US company
Opportunity to benefit from:
• Proven products with long market exclusivity tail
• High gross margins and strong cash flow generation
• Established global supply chain and commercial infrastructure
• Ready-to-deploy US commercialization strategy
This represents a rare chance to invest in a specialized, revenue-generating respiratory platform with FDA-approved products, limited competitive risk, and significant near-term value creation potential in the large and growing US respiratory therapeutics market.